Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Restructuring

The pharmaceutical and biotech sectors are experiencing a significant wave of layoffs and restructuring efforts as companies adapt to challenging market conditions and shift strategic priorities. This comprehensive overview examines the latest developments across the industry, highlighting key trends and their potential impact on the sector's future.

NoahAI News10/2/2025

Novartis Secures FDA Approval for Oral BTK Inhibitor Rhapsido in Chronic Hives Treatment

Novartis has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of Rhapsido (remibrutinib), the first oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU), also known as chronic hives. This approval marks a new era in the management of CSU, offering patients a more convenient alternative to existing injectable therapies.

NoahAI News10/2/2025

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Partnership with Heartseed Amid Strategic Restructuring

Novo Nordisk has announced the termination of its $598 million collaboration with Japanese biotech Heartseed, marking a significant shift in the pharmaceutical giant's strategic focus. The decision comes as part of a broader restructuring initiative led by Novo's new CEO, Maziar Mike Doustdar, aimed at concentrating resources on the company's core business areas of diabetes and obesity.

NoahAI News10/2/2025

Aerska Launches with $21M to Advance Brain-Targeted RNA Therapeutics

Dublin-based biotech startup Aerska has emerged from stealth mode, announcing a $21 million seed funding round to develop its innovative platform for delivering RNA interference (RNAi) medicines across the blood-brain barrier. The company aims to tackle challenging neurological diseases by combining advanced RNAi chemistry with receptor-mediated shuttling and precision medicine approaches.

NoahAI News10/2/2025

General Catalyst's HATCo Completes $515 Million Acquisition of Summa Health, Marking First VC-Owned Hospital System

General Catalyst's Health Assurance Transformation Company (HATCo) has finalized its acquisition of Summa Health, an Ohio-based integrated health system, in a landmark $515 million deal. The transaction, which closed on October 1, 2025, marks a significant milestone in the healthcare industry as Summa Health becomes the first hospital system to be owned by a venture capital firm.

NoahAI News10/2/2025

Illumina Launches AI-Driven BioInsight Division for Multi-Omic Drug Discovery

Illumina, a leading genomics company, has announced the launch of BioInsight, a new informatics and artificial intelligence (AI) software business aimed at revolutionizing drug discovery through multi-omic data analysis. This strategic move comes as the company expands its capabilities beyond DNA sequencing, positioning itself at the forefront of the rapidly evolving biopharmaceutical landscape.

NoahAI News10/2/2025

FDA Rejects Cyprium-Sentynl's Menkes Disease Treatment Due to Manufacturing Issues

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for CUTX-101, a copper histidinate drug candidate developed by Cyprium Therapeutics and Sentynl Therapeutics for the treatment of Menkes disease. The decision, centered on manufacturing deficiencies, halts progress towards what could have been the first approved treatment for this rare and often fatal pediatric condition.

NoahAI News10/2/2025

Boston Scientific Unveils Plans for Next-Generation Watchman Device, Targets Market Expansion

Boston Scientific has announced plans for a new version of its Watchman device, aiming to launch the next-generation system in late 2027 or early 2028. The company also revealed strategies to expand its market reach and enhance the device's capabilities through ongoing clinical trials and potential label expansions.

NoahAI News10/2/2025

Pharmaceutical Giants Join Forces in AI-Driven Drug Discovery Initiative

Bristol Myers Squibb, Takeda, and Astex Pharmaceuticals have announced their participation in the Federated OpenFold3 Initiative, a collaborative artificial intelligence project aimed at revolutionizing drug discovery. This move sees them joining industry leaders AbbVie and Johnson & Johnson in a concerted effort to harness the power of pooled data and advanced AI models.

NoahAI News10/2/2025

Voice AI Startup Assort Health Secures $102M in Funding to Revolutionize Healthcare Call Centers

Assort Health, a cutting-edge voice AI startup, has successfully raised $76 million in a Series B funding round, bringing its total funding to an impressive $102 million in just four months. The company, which specializes in automating healthcare call centers with specialty-specific voice AI agents, is poised to transform patient engagement and streamline healthcare operations.

NoahAI News10/2/2025

Takeda Exits Cell Therapy Arena in Strategic Shift, Reflecting Industry Trend

Takeda Pharmaceutical Company has announced its withdrawal from the cell therapy field as part of a strategic portfolio reprioritization. This move, revealed on October 1, 2025, aligns with a broader industry trend of major pharmaceutical companies reassessing their involvement in cell therapy development.

NoahAI News10/2/2025

Halozyme Acquires Elektrofi in $900M Deal, Expanding Subcutaneous Drug Delivery Capabilities

In a significant move that promises to reshape the landscape of subcutaneous drug delivery, Halozyme Therapeutics has announced its acquisition of Elektrofi for up to $900 million. The deal, which includes an upfront cash payment of $750 million and potential milestone payments totaling $150 million, marks a pivotal step in Halozyme's strategic expansion and diversification of its drug delivery technology portfolio.

NoahAI News10/2/2025

«1...38 39 40...67 »